Genzyme is spending $700 million dollars to buy a chunk of Alnylam Pharmaceuticals of Cambridge — a much smaller company that been moving rapidly toward commercializing treatments for rare genetic diseases.
Sanofi CEO Chris Viehbacher says research departments have been consolidated here to be near universities.
Harvard University is stepping up its efforts to innovate.
Analysts say Genzyme’s decision to manufacture a third drug at it’s Allston facility eventually led to its sale.
After nine months of denials, rejection, bickering and finally, discussion, French pharmaceutical company Sanofi-Aventis of Paris has signed a deal to buy Genzyme of Cambridge for $20.1 billion plus other milestone payments in the future.
Cambridge-based biotechnology company Genzyme is being bought by French drug maker Sanofi-Aventis for $20.1 billion, ending months of corporate haggling.
WBZ News Radio’s Bob Gough, in for Financial Editor Dave Caruso takes a look at the sale of Cambridge-based Genzyme.
Sanofi-Aventis extended its unsolicited $18.5 billion takeover offer for Cambridge biotech company Genzyme Corp. Monday.
Raytheon announced a series of layoffs Tuesday just days after Gov. Deval Patrick denied asking it to delay terminations until after the election.
Biotechnology company Genzyme is cutting 392 positions as it starts the first phase of a plan to eliminate 1,000 by the end of next year.